A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.

We're inching closer to having the first-ever needle-free weight loss drug.

That's thanks to Novo Nordisk , which expects a U.S. approval for its daily pill for chronic weight management by the end of this year. The company expects to launch it in early 2026.

The drug is the 25-milligram oral version of semaglutide, the active ingredient in the Danish drugmaker's popular weight loss injection Wegovy and diabetes counterpart Ozempic.

Several drugmakers, including Novo Nordisk's chief rival Eli Lilly , have been racing to develop obesity pills , which may help alleviate th

See Full Page